The Efficacy and Tolerability of Fixed Dose Irbesartan Hydrochlorothiazide in the Management of Hypertension

Creative Commons License

Canpolat U., Kabakcı M. G.

Clinical Medicine Reviews in Vascular Health, vol.4, pp.73-79, 2012 (Peer-Reviewed Journal)


Hypertension is one of the most important and prevalent major cardiovascular risk factors. It is also a risk factor for medical

problems leading to a marked increase in cardiovascular risk. Thus, appropriate and effcacious management of patients with hypertension is important. There is also an ongoing debate regarding whether major drug subgroups differ in their ability to protect against total

cardiovascular risk or etiology-specifc cardiovascular events, such as stroke and myocardial infarction. Hypertension guidelines, based

on experience from clinical trials, recognize that many individuals will require $2 antihypertensive agents at appropriate doses, either

in fxed combination or as separate prescriptions, to achieve their BP goal, particularly in patients at high cardiovascular risk. If possible,

initiation of fxed-dose combinations should be chosen, because of the advantages for compliance to treatment. In this context, we aimed

to review fxed-dose combinations of irbesartan/hydrochlorothiazide in the management of hypertension.